<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Genetics</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Genetics</journal-title><trans-title-group xml:lang="ru"><trans-title>Генетика</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0016-6758</issn><issn publication-format="electronic">3034-5103</issn><publisher><publisher-name xml:lang="en">The Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">666894</article-id><article-id pub-id-type="doi">10.31857/S0016675823020030</article-id><article-id pub-id-type="edn">KXCFZW</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>ГЕНЕТИКА ЧЕЛОВЕКА</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Gene–Gene Interactions and Biological Network Analysis of Diseases with Disturbances of Human Cognitive Functions</article-title><trans-title-group xml:lang="ru"><trans-title>Межгенные взаимодействия и биологические сети заболеваний с нарушениями когнитивных функций человека</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bocharova</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Бочарова</surname><given-names>А. В.</given-names></name></name-alternatives><email>anna.bocharova@medgenetics.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stepanov</surname><given-names>V. A.</given-names></name><name xml:lang="ru"><surname>Степанов</surname><given-names>В. А.</given-names></name></name-alternatives><email>anna.bocharova@medgenetics.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute of Medical Genetics, Tomsk National Research 
Medical Center of the Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт медицинской генетики, Томский национальный исследовательский медицинский центр Российской академии наук</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-02-01" publication-format="electronic"><day>01</day><month>02</month><year>2023</year></pub-date><volume>59</volume><issue>2</issue><fpage>217</fpage><lpage>225</lpage><history><date date-type="received" iso-8601-date="2025-02-26"><day>26</day><month>02</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, А.В. Бочарова, В.А. Степанов</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, А.В. Бочарова, В.А. Степанов</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">А.В. Бочарова, В.А. Степанов</copyright-holder><copyright-holder xml:lang="ru">А.В. Бочарова, В.А. Степанов</copyright-holder></permissions><self-uri xlink:href="https://transsyst.ru/0016-6758/article/view/666894">https://transsyst.ru/0016-6758/article/view/666894</self-uri><abstract xml:lang="en"><p id="idm45181324013440">Neurological and mental diseases, such as schizophrenia, Alzheimer’s disease, bipolar disorder, Parkinson’s disease, have complex phenotypes with cognitive impairment. These diseases are socially significant pathologies and serious problems for world health and are distinguished by the multilevel nature of the implementation of genetic information. A number of active genes are involved in the formation of the final phenotype. Thereby, it is necessary to apply the analysis of biological networks aimed at identifying the interacting genes and proteins that lead to the pathogenesis of the disease, in order to understand the molecular mechanisms underlying the studied pathology. In this study, various online resources and databases were used to implement this approach: WebGestalt, Gene Ontology, STRING. The protein-protein interaction network was obtained, where two subnets are distinguished, one of which is involved in the risk of developing schizophrenia, and the other in the risk of developing Alzheimer’s disease.</p></abstract><trans-abstract xml:lang="ru"><p id="idm45181324012272">Расстройства неврологического и психического спектра, такие как шизофрения, болезнь Альцгеймера, биполярное расстройство, болезнь Паркинсона, представляют собой сложно наследуемые многофакторные заболевания человека с нарушениями когнитивных функций и являются социально значимыми патологиями, представляющими серьезную проблему для мирового здравоохранения. Данные заболевания отличаются многоуровневым характером реализации генетической информации, и в формировании окончательного фенотипа принимает участие целый ряд совместно действующих генов. В связи с этим для понимания молекулярных механизмов, лежащих в основе изучаемой патологии, следует применить анализ биологических сетей, направленный на выявление взаимодействующих генов, продукты которых приводят к развитию заболевания. В настоящем исследовании для реализации такого подхода в отношении фенотипов с нарушениями когнитивных функций человека были использованы различные онлайн-ресурсы и базы данных: WebGestalt, GeneOnto-logy, STRING. С помощью биоинформатических инструментов была получена сеть белок-белковых взаимодействий, где выделяются две подсети, одна из которых участвует в риске развития шизофрении, а другая – в риске развития болезни Альцгеймера.</p></trans-abstract><kwd-group xml:lang="en"><kwd>сognitive functions</kwd><kwd>cognitive impairment</kwd><kwd>schizophrenia</kwd><kwd>Alzheimer’s disease</kwd><kwd>biological networks.</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>когнитивные функции</kwd><kwd>когнитивные нарушения</kwd><kwd>шизофрения</kwd><kwd>болезнь Альцгеймера</kwd><kwd>биологические сети</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Morozova A., Zorkina Y., Abramova O. et al. Neurobiological highlights of cognitive impairment in psychiatric disorders // Int. J. Mol. Sci. 2022. V. 23. № 3. P. 1217. https://doi.org/10.3390/ijms23031217</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Pettersson E., Lichtenstein P., Larsson H. et al. Genetic influences on eight psychiatric disorders based on family data of 4 408 646 full and half-siblings, and genetic data of 333 748 cases and controls // Psychol. Med. 2019. V. 49. № 7. P. 1166–1173. https://doi.org/10.1017/S0033291718002039</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Nalls M.A., Blauwendraat C., Vallerga C.L. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: A meta-analysis of genome-wide association studies // Lancet Neurol. 2019. V. 18. № 12. P. 1091–1102. https://doi.org/10.1016/S1474-4422(19)30320-5</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Gatz M., Reynolds C.A., Fratiglioni L. et al. Role of genes and environments for explaining Alzheimer disease // Arch. Gen.Psychiatry. 2006. V. 63. № 2. P. 168–174. https://doi.org/10.1001/archpsyc.63.2.168</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Степанов В.А., Бочарова А.В., Марусин А.В. и др. Репликативный анализ ассоциаций генетических маркеров когнитивных признаков с болезнью Альцгеймера в российской популяции // Мол. биология. 2014. Т. 48. № 6. С. 952–962. https://doi.org/10.7868/S0026898414060160</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Степанов В.А., Бочарова А.В., Садуакасова К.З. и др. Репликативное исследование подверженности шизофрении с ранним началом у казахов // Генетика. 2015. Т. 51. № 2. С. 227–235. https://doi.org/10.7868/S0016675815020149</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Бочарова А.В., Марусин А.В., Макеева О.А. и др. Генетические варианты, связанные с нарушениями когнитивных функций человека, при болезни Альцгеймера // Мед. генетика. 2018. Т. 17. № 1. С. 14–19. https://doi.org/10.25557/2073-7998.2018.01.14-19</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Бочарова А.В., Марусин А.В., Иванова С.А. и др. Генетические варианты генов TCF4, LSM1 и CCDC60 ассоциированы с шизофренией // Мед. генетика. 2020. Т. 19. № 4. С. 17–19. https://doi.org/10.25557/2073-7998.2020.04.17-19</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Bocharova A., Vagaitseva K., Marusin F. et al. Association and gene-gene interactions study of late-onset Alzheimer’s disease in the russian population // Genes. 2021. V. 12. P. 1647. https://doi.org/10.3390/genes12101647</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Бочарова А.В., Степанов В.А. Генетическое разнообразие популяций Северной Евразии по маркерам, ассоциированным с заболеваниями, нарушающими когнитивные функции человека // Генетика. 2021. Т. 57. № 9. С. 1062–1072. https://doi.org/10.31857/S0016675821080026</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Бочарова А.В., Степанов В.А. Современные исследования генетики многофакторных заболеваний, связанных с нарушением когнитивных функций человека // Сиб. журн. клинич. и эксперим. медицины. 2021. № 4. Р. 37–44.https://doi.org/10.29001/2073-8552-2021-36-4-37-44</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Liao Y., Wang J., Jaehnig E.J. et al. WebGestalt 2019: Gene set analysis toolkit with revamped UIs and APIs // Nucl Acids. Res. 2019. V. 47. № W1. P. W199–W205. https://doi.org/10.1093/nar/gkz401</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Szklarczyk D., Gable A.L., Lyon D. et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets // Nucl. Acids Res. 2019. V. 47. № D1. P. D607–D613. https://doi.org/10.1093/nar/gky1131</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ashburner M., Ball C.A., Blake J.A. et al. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium // Nat. Genet. 2000. V. 25. № 1. P. 25–29. https://doi.org/10.1038/75556</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Bliss T.V., Cooke S.F. Long-term potentiation and long-term depression: A clinical perspective // Clinics (Sao Paulo). 2011. V. 66. Suppl. 1. P. 3–17. https://doi.org/10.1590/s1807-59322011001300002</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Alkadhi K.A. Neuroprotective effects of nicotine on hippocampal long-term potentiation in brain disorders // J. Pharmacol. Exp. Ther. 2018. V. 366. № 3. P. 498–508. https://doi.org/10.1124/jpet.118.247841</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Cleary J.P., Walsh D.M., Hofmeister J.J. et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function // Nat. Neurosci. 2005. V. 8. № 1. P. 79–84. https://doi.org/10.1038/nn1372</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Cullen W.K., Suh Y.H., Anwyl R., Rowan M.J. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments // Neuroreport. 1997. V. 8. № 15. P. 3213–3217. https://doi.org/10.1097/00001756-199710200-00006</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>https://phgkb.cdc.gov/PHGKB/hNHome.action</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>O’Donovan M.C., Craddock N., Norton N. et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up // Nat. Genet. 2008. V. 40. № 9. P. 1053–1055. https://doi.org/10.1038/ng.201</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Matthews J.M., Sunde M. Zinc fingers-folds for many occasions // IUBMB Life. 2002. V. 54. № 6. P. 351–355. https://doi.org/10.1080/15216540216035</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Федотова А.А., Бончук А.Н., Могила В.A., Георгиев П.Г. Белки с цинковыми пальцами типа С2Н2 – самый многочисленный и наименее изученный класс транскрипционных факторов высших эукариот // Acta Naturae. 2017. Т. 9. № 2. С. 50–61.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Deans P.J.M., Raval P., Sellers K.J. et al. Psychosis risk candidate ZNF804A localizes to synapses and regulates neurite formation and dendritic spine structure // Biol. Psychiatry. 2017. V. 82. № 1. P. 49–61. https://doi.org/10.1016/j.biopsych.2016.08.038</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Penzes P., Cahill M.E., Jones K.A. et al. Dendritic spine pathology in neuropsychiatric disorders // Nat. Neurosci. 2011. V. 14. № 3. P. 285–293. https://doi.org/10.1038/nn.2741</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Chang H., Xiao X., Li M. The schizophrenia risk gene ZNF804A: Clinical associations, biological mechanisms and neuronal functions // Mol. Psychiatry. 2017. V. 22. № 7. P. 944–953. https://doi.org/10.1038/mp.2017.19</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Srivastava D.P., Woolfrey K.M., Penzes P. Analysis of dendritic spine morphology in cultured CNS neurons // J. Vis. Exp. 2011. V. 53. P. e2794. https://doi.org/10.3791/2794</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Zhou D., Xiao X., Li M. The schizophrenia risk isoform ZNF804AE3E4 affects dendritic spine // Schizophrenia Res. 2020. V. 218. P. 324–325. https://doi.org/10.1016/j.schres.2019.12.038</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Tao R., Cousijn H., Jaffe A.E. et al. Expression of ZNF804A in human brain and alterations in schizophrenia, bipolar disorder, and major depressive disorder: A novel transcript fetally regulated by the psychosis risk variant rs1344706 // JAMA Psychiat. 2014. V. 71. № 10. P. 1112–1120. https://doi.org/10.1001/jamapsychiatry.2014.1079</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Corder E.H., Saunders A.M., Strittmatter W.J. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families // Science. 1993. V. 261. № 5123. P. 921–923. https://doi.org/10.1126/science.8346443</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Strittmatter W.J., Weisgraber K.H., Huang D.Y. et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease // Proc. Natl Acad. Sci. USA. 1993. V. 90. № 17. P. 8098–8102. https://doi.org/10.1073/pnas.90.17.8098</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Roses A.D. Apolipoprotein E alleles as risk factors in Alzheimer’s disease // Annu. Rev. Med. 1996. V. 47. P. 387–400. https://doi.org/10.1146/annurev.med.47.1.387</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Kecmanović M., Dobricić V., Dimitrijević R. et al. Schizophrenia and apolipoprotein E gene polymorphism in Serbian population // Int. J.Neurosci. 2010. V. 120. № 7. P. 502–506. https://doi.org/10.3109/00207451003765956</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Gibbons A.S., Udawela M., Jeon W.J. et al. The neurobiology of APOE in schizophrenia and mood disorders // Front Biosci. (Landmark Ed). 2011. V. 16. P. 962–979. https://doi.org/10.2741/3729</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Giau V.V., Bagyinszky E., An S.S., Kim S.Y. Role of apolipoprotein E in neurodegenerative diseases // Neuropsychiatr. Dis. Treat. 2015. V. 11. P. 1723–1737. https://doi.org/10.2147/NDT.S84266</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Yin Y., Wang Z. ApoE and neurodegenerative diseases in aging // Adv. Exp. Med. Biol. 2018. V. 1086. P. 77–92. https://doi.org/10.1007/978-981-13-1117-8_5</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Xu M.Q., St Clair D., He L. Meta-analysis of association between ApoE epsilon4 allele and schizophrenia // Schizophr. Res. 2006. V. 84. № 2–3. P. 228–235. https://doi.org/10.1016/j.schres.2006.02.015</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Allen N.C., Bagade S., McQueen M.B. et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database // Nat. Genet. 2008. V. 40. № 7. P. 827–834. https://doi.org/10.1038/ng.171</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Lambert J.C., Ibrahim-Verbaas C.A., Harold D. et al. Meta-analysis of 74 046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease // Nat. Genet. 2013. V. 45. № 12. P. 1452–1458. https://doi.org/10.1038/ng.2802</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Abyadeh M., Djafarian K., Heydarinejad F. et al. Association between apolipoprotein E gene polymorphism and Alzheimer’s disease in an Iranian population: A Meta-Analysis // J. Mol. Neurosci. 2019. V. 69. № 4. P. 557–562. https://doi.org/10.1007/s12031-019-01381-1</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Ishii K., Kubo K., Nakajima K. Reelin and neuropsychiatric disorders // Front. Cell Neurosci. 2016. V. 10. P. 229. https://doi.org/10.3389/fncel.2016.00229</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Ovadia G., Shifman S. The genetic variation of RELN expression in schizophrenia and bipolar disorder // PLoS One. 2011. V. 6. P. e19955. https://doi.org/10.1371/journal.pone.0019955</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Bufill E., Roura-Poch P., Sala-Matavera I. et al. Reelin signaling pathway genotypes and Alzheimer disease in a Spanish population // Alzheimer Dis. Assoc. Disord. 2015. V. 29. № 2. P. 169–172. https://doi.org/10.1097/WAD.0000000000000002</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Saez-Valero J., Costell M., Sjogren M. et al. Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer’s disease// J. Neurosci. Res. 2003. V. 72. № 1. P. 132–136. https://doi.org/10.1002/jnr.10554</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Seripa D., Matera M.G., Franceschi M. et al. The RELN locus in Alzheimer’s disease // J.Alzheimers. Dis. 2008. V. 14. № 3. P. 335–344. https://doi.org/10.3233/jad-2008-14308</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Botella-López A., Cuchillo-Ibáñez I., Cotrufo T. et al. Beta-amyloid controls altered Reelin expression and processing in Alzheimer’s disease // Neurobiol. Dis. 2010. V. 37. № 3. P. 682–691. https://doi.org/10.1016/j.nbd.2009.12.006</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Pujadas L., Rossi D., Andrés R. et al. Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer’s disease // Nat. Commun. 2014. V. 5. P. 3443. https://doi.org/10.1038/ncomms4443</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Rossi D., Gruart A., Contreras-Murillo G. et al. Reelin reverts biochemical, physiological and cognitive alterations in mouse models of Tauopathy // Prog. Neurobiol. 2020. V. 186. P. 101743. https://doi.org/10.1016/j.pneurobio.2019.101743</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Roth T.L., Lubin F.D., Sodhi M., Kleinman J.E. Epigenetic mechanisms in schizophrenia // Biochim. Biophys. Acta. 2009. V. 1790. P. 869–877. https://doi.org/10.1016/j.bbagen.2009.06.009</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Veldic M., Guidotti A., Maloku E. et al. In psychosis, cortical interneurons overexpress DNA-methyltransferase 1 // Proc. Natl Acad. Sci. USA. 2005. V. 102. № 6. P. 2152–2157. https://doi.org/10.1073/pnas.0409665102</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Impagnatiello F., Caruncho H., Niu S. et al. Reelin promotes hippocampal dendrite development through the VLDLR/ApoER2-Dab1 pathway // Neuron. 2004. V. 41. P. 71–84. https://doi.org/10.1016/s0896-6273(03)00819-5</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia // Arch. Gen. Psychiatry. 2000. V. 57. P. 65–73. https://doi.org/10.1001/archpsyc.57.1.65</mixed-citation></ref></ref-list></back></article>
